Skip to content
Syntara
A clinical‐stage drug development company primarily focused on blood related cancers.
SyntaraSyntara
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact

March 2025 Quarterly Webinar Replay

You are here:
  1. Home
  2. Media
  3. March 2025 Quarterly Webinar Replay

March 2025 Quarterly Webinar Replay 

Share

Linkedin
Ask me anything

Submit

Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.

Highlights

Preliminary analysis of SNT-4728 iRBD Phase 2 study results provides encouraging signs of reduced brain inflammation

Read More »

SNT-9465 hypertrophic skin scarring trial exceeds 50% recruitment

Read More »

Investor Update Webinar

Read More »

Subscribe to our news

Subscribe

Syntara is a clinical stage drug development company focused on haematological malignancies.

Linkedin

ABN 75 082 811 630

Quick Links
  • Pipeline
  • Investors
  • Highlights
  • Pipeline
  • Investors
  • Highlights
Subscribe to our News
Get In Touch
  • Locked Bag 5015 
    Frenchs Forest 
NSW 2086
    AUSTRALIA
  • info@syntaratx.com.au 
  • +61 2 8760 1480

2026 © Syntara Limited.

Legal

Go to Top